{"id":"gc5107","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GC5107 binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, leading to improved glycemic control. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.","oneSentence":"GC5107 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon release to lower blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:49.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04565015","phase":"PHASE3","title":"Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"GC Biopharma Corp","startDate":"2020-12-21","conditions":"Primary Immune Deficiency","enrollment":24},{"nctId":"NCT02783482","phase":"PHASE3","title":"Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2016-10","conditions":"Immunologic Deficiency Syndromes","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GCC 10% IGIV","Immune Globulin Intravenous (Human), 10% Liquid","IGIV","Immune globulin intravenous (human) solution, 10% liquid"],"phase":"phase_3","status":"active","brandName":"GC5107","genericName":"GC5107","companyName":"GC Biopharma Corp","companyId":"gc-biopharma-corp","modality":"Biologic","firstApprovalDate":"","aiSummary":"GC5107 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon release to lower blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}